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Tolfenamic acid lowers the levels of the amyloid precursor protein (APP) and amyloid beta (Ab) when
administered to C57BL/6 mice by lowering their transcriptional regulator speciﬁcity protein 1 (SP1). To
determine whether changes upstream in the amyloidogenic pathway that forms Ab plaques would
improve cognitive outcomes, we administered tolfenamic acid for 34 days to hemizygous R1.40 trans-
genic mice. After the characterization of cognitive deﬁcits in these mice, assessment of spatial learning
and memory functions revealed that treatment with tolfenamic acid attenuated long-term memory and
working memory deﬁcits, determined using Morris water maze and the Y-maze. These improvements
occurred within a shorter period of exposure than that seen with clinically approved drugs. Cognitive
enhancement was accompanied by reduction in the levels of the SP1 protein (but not messenger RNA
[mRNA]), followed by lowering both the mRNA and the protein levels of APP and subsequent Ab levels.
These ﬁndings provide evidence that tolfenamic acid can disrupt the pathologic processes associated
with Alzheimer’s disease (AD) and are relevant to its scheduled biomarker study in AD patients.
 2013 Elsevier Inc. All rights reserved.1. Introduction
Alzheimer’s disease (AD) represents the most prevalent neuro-
degenerative disease in the elderly. During the course of the disease,
memory, cognitive performance, and other daily activities are all
impaired as a result of extensive neuronal loss (Berg et al., 1993;
Braak and Braak, 1997; Nelson et al., 2012). AD is characterized by
the presence of neuropathologic deposits consisting of extracellular
senile plaques of amyloid beta (Ab) core and intraneuronal neuro-
ﬁbrillary tangles, especially in the cerebral cortex, hippocampus,
subcortical nuclei, and amygdala (Ballard et al., 2011; Harrington,
2012; Reddy et al., 2010; Selkoe, 2001).
The amyloid precursor protein (APP) is processed by the beta-
site APP-cleaving enzyme 1 (BACE1) and g-secretase to generate
various Ab peptide isoforms that can accumulate resulting in the
formation of the insoluble aggregates of amyloid plaques (Querfurth
and LaFerla, 2010; Shoji et al., 1992; Urbanc et al., 1999; Zhang et al.,
2012). Ab1e40 and Ab1e42 are the major generated isoforms with
Ab1e42 found to be more aggregative triggering amyloid plaque
formation (Finder and Glockshuber, 2007; Naslund et al., 2000).Laboratory, Department of
f Rhode Island, 7 Greenhouse
9; fax: þ1 (401) 874 5787.
ll rights reserved.Accumulation of Ab into amyloid plaques initiates a pathologic
cascade resulting in synaptic dysfunction and neuronal death that
contribute to the neurodegeneration observed in AD according to
the amyloid hypothesis (Hardy and Higgins, 1992; Selkoe, 2001).
However, other studies suggest that Ab-soluble oligomers and
aggregates are the toxic species and that in AD patients soluble Ab
levels highly correlate with disease severity markers (Kroth et al.,
2012; McLean et al., 1999).
Food and drug administration (FDA)eapproved drugs for treat-
ment of AD include 4 cholinesterase inhibitors and 1 N-methyl-D-
aspartate receptor antagonist. However, these medications are not
disease modifying, and they do not stop the progression of AD
(Ozudogru and Lippa, 2012). Current research focuses on inter-
ventions that target Ab production and aggregation and the pro-
duction of hyperphosphorylated tau (Gotz et al., 2012; Ozudogru
and Lippa, 2012; Roberson and Mucke, 2006); however, no thera-
peutic strategy has explored more upstream interventions at the
transcriptional level. Speciﬁcity protein 1 (SP1) coactivates the
transcription of APP, BACE1, and tau genes (Christensen et al., 2004;
Docagne et al., 2004; Heicklen-Klein and Ginzburg, 2000), and
consequently, changes in its levels can alter the downstream pa-
thways related to amyloidogensis (Adwan et al., 2011; Basha et al.,
2005) and tau pathology (unpublished data). Tolfenamic acid,
a nonsteroidal anti-inﬂammatory drug (NSAID), induces the deg-
radation of SP1 protein (Abdelrahim et al., 2006), and data from our
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micewith tolfenamic acid lowered the levels of cerebral SP1 and the
expression of AD-related Sp1 target genes such as APP (Adwan et al.,
2011).
Transgenic mouse models of AD are useful for elaborating
mechanisms involved in the development and progression of AD. In
addition, they allow for testing of new therapies in vivo to provide
more accurate data for testing in human clinical trials (Duff and
Suleman, 2004; Hock and Lamb, 2001). Our previous studies were
conducted in wild-type C57BL/6 mice that do not exhibit AD
pathology; so, we could not assess for cognitive function improve-
ment associated with an amyloidogenic pathway. Thus, we decided
to examine the ability of tolfenamic acid to lower AD proteins,
including SP1, APP, and Ab, and to examinewhether such reductions
are commensurate with improvements in cognitive functions in
a mouse model of AD. Because the endogenous APP promoter is
largely driven by SP1 (Docagne et al., 2004), we chose to study the
effects of tolfenamic acid (which degrades SP1) in the hemizygous
R1.40 mice, a genomic-base transgenic mouse model that harbors
the Swedish mutation APPK670N/M671L, driven by the human APP
promoter (Lamb et al., 1993).
Therefore, after the characterization of learning and memory
impairment in female hemizygous R1.40 transgenic mice, 5 and
50 mg/kg/d tolfenamic acid was administered to female R1.40 mice
aging between 14 and 21 months via oral gavage for 34 days and
learning and memory functions were assessed in the Morris water
maze (MWM) and the Y-maze. On day 35, mice were euthanized
and AD-associated proteins including SP1, APP, and soluble and
insoluble Ab1e40 and Ab1e42 were assessed in the frontal cortex,
which displays extensive AD pathology in this animal model
(Kulnane and Lamb, 2001; Lehman et al., 2003).
2. Methods
2.1. Animal model
The transgenic mouse model R1.40 was used for this study. The
rationale for choosing this transgenic line relies on the fact that the
mutant human APP gene is driven by its endogenous human
promoter unlike most of other transgenic lines, which use hamster
PrP or murine Thy-1 promoters (Hock and Lamb, 2001). The human
promoter region has numerous CpG boxes that SP1 binds to
whilst activating gene expression. Thus, R1.40 is an ideal mouse
model to conduct experiments on, as tolfenamic acid lowers SP1 and
thus alters upstream transcriptional pathways of APP. These trans-
genic mice, B6.129-Tg(APPSw)40btla/J, were obtained from the
Jackson laboratory (Bar Harbor, ME, USA), and colonies of hemi-
zygous and homozygous strains were established in-house. R1.40 is
a genomic-based transgenic mouse model that was developed by
Bruce T. Lamb; it uses a yeast artiﬁcial chromosome that contains the
full 400-kbhumanAPPgene andﬂanking sequence of approximately
250 kb to harbor the Swedishmutation APPK670N/M671L, including
the human transcriptional regulatory elements needed for proper
spatial and temporal expression (Hock and Lamb, 2001; Lamb et al.,
1997; Reaume et al., 1996). The developed hemizygous R1.40 line
shows a signiﬁcant increase in APP and Ab production as early as 3
months of agewithAbplaque deposition occurring at 24e26months
of age compared with the wild-type mice. Furthermore, the mne-
monic deﬁcits in R1.40 were similar to those observed in AD (Hock
et al., 2009; Lamb et al., 1999).
To establish R1.40 transgenic mice colonies, mice were bred and
genotyped in-house at the University of Rhode Island (URI). To
ensure the accuracy of genotyping results, 2 genotyping techniques
were performed: standard polymerase chain reaction (PCR) fol-
lowed by gel electrophoresis on 1.5% agarose gel and the TaqManallelic discrimination assay (Applied Biosystems, Foster City, CA,
USA; for details, see Supplementary data). Animals of mixed
genotypes were housed in standard mouse cages in the URI animal
quarter rooms with a 12:12 hour light-dark cycle (light on at 6:00
AM, light off at 6:00 PM). Temperature was maintained at 22  2 C
with humidity levels of 55%  5%, and food and water were avail-
able for mice ad libitum. The University of Rhode Island Institu-
tional Animal Care and Use Committee approved all protocols
including the breeding and genotyping methods. Animals were
under continuous supervision by a URI veterinarian during the
entire study and during drug administration.
2.2. Assessment of cognitive deﬁcits in hemizygous R1.40 transgenic
mice
To characterize memory and cognitive deﬁcits in the hemi-
zygous, R1.40, transgenic mouse model, behavioral testing in mazes
that are reliant on the integrity of the hippocampus and brain
cortex was conducted using the MWM and spontaneous alterna-
tions in the Y-maze. Preliminary studies showed cognitive deﬁcits
in both male and female mice, and the drug under study was active
in both genders. In this study, we decided to use a single gender to
minimize any possible inﬂuence or interference that may be
created because of the use of mixed genders in the experiments.
Thus, female, hemizygous, APP transgenic (n ¼ 19) and female,
control wild-type (n ¼ 18) groups of ages ranging between 9 and
20 months were used.
2.2.1. Morris water maze
We have tested the mice in the hidden version of the MWM. In
this task, the mice had to locate the hidden platform by learning
multiple spatial relationships between the platform and the distal
extramaze cues (Gulinello et al., 2009; Laczo et al., 2009; Vorhees
and Williams, 2006). The apparatus consisted of a white 4800
diameter pool that is 3000 in height and was ﬁlled with water to
a depth of 1400. The water was kept opaque by the addition of white,
nontoxic liquid washable paint. The pool was surrounded by
distinct ﬁxed visual cues that the animals used to navigate to reach
the escape platform. A clear Plexiglas platform 10 cm2 was kept
submerged 0.5 cm below the surface of the water. The temperature
of the water was maintained at 25  2 C during all experiments in
the water maze. On day 15 of tolfenamic acid administration, mice
received a habituation trial in which they were allowed to swim
freely for 60 seconds. On the following day and for a total of 8 days,
mice received training sessions of 3 trials daily. The starting posi-
tion for each trial was randomly assigned between the 4 possible
positions (1 per quadrant), whereas the platform positionwas ﬁxed
in each trial. Each animal was allowed to swim until they found
the immersed hidden platform or for a maximum duration of
60 seconds. If the mouse failed to locate the platform, it would
be gently guided to sit on the platform for a maximum duration
of 30 seconds. Mice were also left to sit on the platform for a
maximum of 10 seconds on successful trial. After completion of the
8 acquisition sessions, probe trials for up to 60 seconds on day 1 and
day 11 after the last day of training were performed to assess long-
term memory retention by studying the preference of the mice for
the correct quadrant that previously contained the hidden platform.
The swim paths and latencies to locate the platform and time spent
in quadrants were videotaped and tracked with a computerized
video-tracking system (ObjectScan; Clever Sys., Inc, Reston, VA,
USA), and the resultant data were analyzed.
2.2.2. Spontaneous alternation in the Y-maze
The spontaneous alternation ratio, deﬁned as the percentage of
the number of arm entries different from the previous 2 entries
Fig. 1. A timeline of tolfenamic acid administration and behavioral assessment. Mice
were administered tolfenamic acid daily for 34 days. Behavioral testing in the Morris
water maze began on Day 15 of dosing with daily training sessions that lasted until Day
23 of the study. We conducted the ﬁrst session of probe trials (Day 1) on Day 24 of
dosing and a second session of probe trials (Day 11) on Day 34 of dosing, to assess for
long-term memory retention. Trials for the spontaneous alternations in the Y-maze
were conducted on Day 33 of dosing as well. Animals were euthanized on Day 35 of the
study, and brain tissue was dissected, collected, and stored in the 80 C freezer.
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et al., 1999), was measured. Testing was conducted in a white Y-
maze with arms that were 1200 (long) by 300 (wide) with 800 high
walls. Mice were placed into 1 of the Y-maze arms and were left to
explore themaze freely for 5minutes. After each trial, themazewas
cleaned with 70% ethanol. Y-maze trials were videotaped and
tracked with a computerized video-tracking system (ObjectScan;
Clever Sys., Inc), and the data were analyzed.2.3. Animal exposure to tolfenamic acid and behavioral testing
Tolfenamic acid was obtained from Sigma Aldrich (St Louis, MO,
USA), and female hemizygous APP yeast artiﬁcial chromosome,
R1.40 transgenicmice aged between 14 and 21monthswere used to
examine the ability of tolfenamic acid to reduce the amyloidogenic
load and to improve the learning and memory deﬁcits of the mice.
From our initial published studies with tolfenamic acid (Adwan
et al., 2011), we found that 5 and 50 mg/kg/d were the optimum
lowand high doses capable to produce reductions in amyloidogenic
proteins.We also found that a treatment duration of 15 dayswas the
minimumperiod required to show signiﬁcant reductions in APP and
Ab. Thus, on day 15 of drug administration, we started conducting
behavioral experiments and tolfenamic acid administration
continued until the last day of the behavioral studies. The animals
were divided into 3 groups of similar age variation and were
administered tolfenamic acid daily via oral gavage for 34 days: ﬁrst
group was administered 5 mg/kg/d tolfenamic acid in corn oil
(n ¼ 6), the second group was administered 50 mg/kg/d tolfenamic
acid in corn oil (n ¼ 7), and the third group was administered the
corn oil vehicle (n ¼ 6). After 14 days of dosing, mice were tested in
theMWM as described in Section 2.2.1. On day 33, mice were tested
for spontaneous alternation in the Y-maze as described in Section
2.2.2. Finally, on day 35, mice were euthanized and brain tissue was
extracted, dissected, and stored at80 C. Fig. 1 provides a timeline
for the experimental events involved in drug administration and
behavioral assessment.2.4. Protein extraction and Western blot analysis
Brain cortices were homogenized with radioimmunoprecip-
itation assay (RIPA) lysis buffer containing 10 mM Tris-HCl (pH 7.4),
150 mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate, 1 mM
ethylenediaminetetraacetic acid, and 0.1% protease inhibitor cocktail.
The homogenates were centrifuged at 10,000 g for 10 minutes at 4C, and supernatants were collected. Protein levels were determined
using the BCA kit (Pierce Biotechnology, Inc, Rockford, IL, USA). Forty
micrograms of total protein was separated on 8% sodium dodecyl
sulfate polyacrylamide gel and then transferred onto polyvinylidiene
diﬂouride membranes (GE Healthcare, Piscataway, NJ, USA). Mem-
branes were blocked using 5% nonfat milk in Tris-buffered saline þ
0.5% Tween-20 (TBST, pH 7.4) for 1 hour. Membranes were then
incubated overnight at 4 Cwith the speciﬁc antibody diluted inTBST
for 1 hour (1:2000 dilution of 6E10 for APP [Covance Research
Products, Inc, Dedham, MA, USA] and 1:500 dilution of 1C6 for SP1
[Santa Cruz Biotechnology, Santa Cruz, CA, USA]). After washing
membranes 4 times with TBST, membranes were incubated for 1
hour with the anti-mouse IRDye 680 (Li-Cor Bioscience, Lincoln, NE,
USA) (1:5000) at room temperature. After washing the membranes
twicewith TBSTand oncewith TBS, the imageswere developedusing
the Li-Cor Odyssey infrared imaging system (Li-Cor Bioscience). The
membranes were also reprobed for b-actin (Sigma Aldrich) at
a dilution of 1:2500 in TBST to obtain the APP/b-actin ratio. The
intensities of the obtained Western blot bands were determined
using Odyssey V1.2 software (Li-Cor Bioscience).
2.5. RNA isolation, synthesis of complementary DNA, and
quantitative real-time PCR
RNA was isolated from cortical tissue after the TRIzol Reagent
method (Invitrogen, Carlsbad, CA, USA), checked for integrity
using NanoDrop 2000 Micro-Volume UV-Vis Spectrophotometer
(Thermo Scientiﬁc, Wilmington, DE, USA) and gel electrophoresis.
RNA was reverse transcribed to complementary DNA (cDNA) using
the iScript Select cDNA Synthesis kit following manufacturer’s
instructions (Bio-Rad, Hercules, CA, USA). About 1000 ng of RNA
was diluted to 19.5 mL with nuclease-free water, and 3 mL oligo (dT)
mix, 6 mL 5 iScript select reaction mix, and 1.5 mL of iScript reverse
transcriptase were added. Samples were incubated at 42 C for 90
minutes and then at 85 C for 5 minutes to terminate the reaction.
All incubations were conducted using MJ Research MiniCycler PTC-
150 (Bio-Rad). Primer pairs for Sp1, APP, and b-actin were obtained
from Invitrogen as follows: Sp1 sense 50-CAAGCC CAA ACA ATC ACC
TT-30 and antisense 50-CAA TGG GTG TGAGAG TGG TG-30, APP sense
50-TGC AGC AGA ACG GATATG AG-30 and antisense 50-ACA CCG ATG
GGT AGT GAA GC-30, b-actin sense 50-TGT TAC CAA CTG GGA CGA
CA-30, and antisense 50-TCT CAG CTG TGGTGGTGA AG-30. Each real-
time PCR reaction mix contained 2 mL of cDNA, 1 mL of each primer,
8.5 mL nuclease-free water, and 12.5 mL SYBR Green PCR Master Mix
(Applied Biosystems). Real-time PCR was conducted using 7500
Real-Time PCR System (Applied Biosystems) following the standard
protocol: 50 C for 2 minutes followed by 95 C for 10 minutes and
then 40 cycles of 95 C for 15 seconds and 60 C for 1 minute.
Results were analyzed using SDS software, and expression data
were reported relative to b-actin messenger RNA (mRNA) using the
2DDCt method.
2.6. Enzyme-linked immunosorbent assay using Ab1e40 and Ab1e42
assay kits
Enzyme-linked immunosorbent assay (ELISA) using human
Ab1e40 and Ab1e42 assay IBL kits JP27713 and JP27711 determined
Ab levels, both soluble and insoluble fractions (Immuno-Biological
Laboratories, Gunma, Japan). These kits are solid-phase sandwich
ELISA with 2 types of highly speciﬁc antibodies that are 100%
reactive with mouse Ab1e40 with a sensitivity of 5.00 pg/mL
(JP27713) and 70% reactive with mouse Ab1e42 with a sensitivity of
4.03 pg/mL (JP27711). The assay conditions were followed accord-
ing to a method described in the literature (Morishima-Kawashima
et al., 2000; Wu et al., 2008). The levels of Ab in the test samples
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2.7. Statistical analysis
Biochemical data are expressed as the mean  the standard error
of the mean (SEM). Assessment of performance in MWM daily
training sessions between the hemizygous R1.40 and the wild-type
groups was determined using repeated-measure analysis of variance
(ANOVA), whereas the signiﬁcance of probe trials differences bet-
ween both groups was determined by a 2-tailed Student t test. The
signiﬁcance of differences among various treatment groups was
determinedby repeated-measureANOVAandTukey-Kramermultiple
comparison a posteriori analysis. All statistical analyses were con-
ducted using GraphPad InStat 3 software (GraphPad Software, La Jolla,
CA, USA); p value of <0.05 was considered statistically signiﬁcant.
3. Results
3.1. Overall safety and toxicity observations
Overt toxic effects of tolfenamic acid administration were not
observed in these animals. No changes in body weight were
observed, and treatment with tolfenamic acid did not result in any
abnormal behavior compared with nonexposed mice. Although the
safety of tolfenamic acid has been previously established, as it has
been used in Europe for decades for rheumatoid arthritis and for
migraine, recent toxicity studies conducted by one of our collabo-
rators showed that chronic administration of tolfenamic acid of
50 mg/kg 3 times a week for 6 weeks did not cause changes in
hematocrit or hemoglobin in tolfenamic acid exposed mice. In
addition, histopathologic analysis showed that acute and chronic
administration of tolfenamic acid did not produce adverse changes
in gastric and intestinal epithelia (unpublished data).
3.2. Hemizygous R1.40 mice exhibit cognitive impairments when
tested in the MWM and in the Y-maze
Spatial navigation in theMWM is one type of tests used to assess
long-term memory functions, which are usually impaired in AD. In
the daily sessions that consisted of 3 trials per day for a total of 8
days, repeated-measure ANOVA indicated no signiﬁcant difference
in the performance, assessed bymeasuring escape latency, between
the transgenic group and the control wild-type mice in this task
(F(7,245) ¼ 0.924, p > 0.05) (Fig. 2A). However, probe trials that
assessed the percent time in the correct quadrant that containedFig. 2. Memory impairments in hemizygous amyloid precursor protein (APP) yeast artiﬁcial
water maze (MWM). (A) Acquisition patterns during daily training. (B) Probe trials for long
indicates that the values are signiﬁcantly different from control, as determined by a Studenthe hidden platform showed that as the retention delay increased
from day 1 after the last day of the daily training sessions to day 11,
the transgenic mice exhibited memory impairment as they failed to
remember the location of the hidden platform. As shown in Fig. 2B,
probe trials in day 1 after the last day of daily training sessions
showed no signiﬁcant difference between both groups (p > 0.1).
However, after a longer delay on day 11 after the last day of daily
trainings sessions, the hemizygous R1.40 transgenic mice signiﬁ-
cantly spent less time (mean ¼ 23%, SEM ¼ 1.99%) compared with
the control wild-type mice (mean¼ 29.8%, SEM¼ 2.58%), p¼ 0.045
(Fig. 2B). In addition, ANOVA of target preference showed that both
WT and R1.40 mice spent signiﬁcantly more time in the correct
quadrant in the ﬁrst probe trial. However, in the second probe trial,
only the WT group retained such signiﬁcant target preference. The
R1.40 mice group failed to maintain target preference indicating
memory impairment (see Supplementary data).
Working memory function was assessed by measuring the
spontaneous alternations in the Y-maze. This task is based on the
innate nature of the mice to visit arms that have not been recently
visited (Hock et al., 2009; King et al., 1999). Results revealed that
hemizygous transgenic R1.40 mice exhibited impaired working
memory function as they had a signiﬁcantly lower spontaneous
alternation ratio (mean ¼ 0.413, SEM ¼ 0.021) than the control
wild-type mice (mean ¼ 0.496, SEM ¼ 0.019), p ¼ 0.0047 (Fig. 3).
3.3. Treatment with tolfenamic acid reverses the cognitive deﬁcits in
hemizygous R1.40 mouse model
We determined previously the presence of impaired behavioral
performance in the hemizygous R1.40 mice. This was manifested by
a decline in the long-term memory and the working memory
functions as identiﬁed by poor retention of the spatial location of
the platform in the MWM and spontaneous alternations in the
Y-maze, respectively.
We further examined the ability of a tolfenamic acid treatment of
5 and 50 mg/kg/d to attenuate these learning and memory deﬁcits
in groups of female hemizygous R1.40 transgenic mice aging
between 14 and 21 months. In the MWM task, there was a signiﬁ-
cant effect of training as ANOVA showed that the difference in
escape latency between the ﬁrst and the last daily training sessions
was statistically signiﬁcant (F(7,144) ¼ 7.833, p < 0.0001). Escape
latency between the treatment and the vehicle groups showed no
signiﬁcant differences in daily learning acquisition (Fig. 4A).
However, ANOVA indicated an improvement in long-term memory
retention in day 11 probe trials (F(2,15)¼ 4.145, p¼ 0.0369) (Fig. 4B).
The Tukey-Kramer HSD post hoc test showed that the mice groupchromosome transgenic mice, line R1.40, assessed by the swimming task in the Morris
-term memory retention on Day 1 and Day 11 after acquisition-training trials. Asterisk
t t test (p < 0.05). Abbreviation: WT, wild type.
Fig. 3. Working memory impairments in hemizygous APP yeast artiﬁcial chromosome
transgenic, line R1.40 mice. Mice were examined for working memory function
assessed by measuring the spontaneous alternation ratio in the Y-maze. Double
asterisks indicate that the values are signiﬁcantly different from control, as determined
by a Student t test (p < 0.01). Abbreviation: WT, wild type.
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improvement (HSD ¼ 3.12, p < 0.05), whereas the treatment with
5 mg/kg/d failed to reach signiﬁcance (HSD¼ 0.71 p> 0.5) (Fig. 4B).
Furthermore, ANOVA of target preference indicated that mice
groups treatedwith 50mg/kg/d spent signiﬁcantlymore time in the
correct quadrant in both probe trials compared with other groups
indicating memory improvement (for details, see Supplementary
data).
Results from the ANOVA of the spontaneous alternation ratio in
the Y-maze showed a signiﬁcant improvement in working memory
(F(2,15) ¼ 4.479, p ¼ 0.0298) (Fig. 5). The Tukey-Kramer HSD post
hoc test revealed a signiﬁcant improvement with tolfenamic acidFig. 4. The administration of tolfenamic acid to hemizygous APP yeast artiﬁcial chro-
mosome R1.40 mice improves spatial memory. Tolfenamic acid was administered by
oral gavage daily for 34 days. For details, see Section 2. (A) Acquisition patterns during
daily training trials of 5 and 50 mg/kg/d and vehicle groups. (B) Probe trials assessing
the long-term memory retention on Day 1 and Day 11 after acquisition-training trials.
Asterisk indicates that values are signiﬁcantly different from vehicle, as determined by
1-way analysis of variance with Tukey-Kramer post hoc test to compare all pairs of
columns (p < 0.05), obtained using GraphPad InStat 3 software. Vehicle n ¼ 6, 5 mg/kg/
d n ¼ 6, and 50 mg/kg/d n ¼ 7.treatment of 50 mg/kg/d (HSD ¼ 4.139, p < 0.05); however, treat-
ment with 5 mg/kg/d did not reach signiﬁcance (HSD ¼ 1.30,
p > 0.05) (Fig. 5).3.4. Tolfenamic acid treatment lowers SP1 protein without altering
Sp1 gene expression
The protein levels of cortical SP1 normalized to b-actin were
analyzed byWestern blot after treatment with 0, 5, and 50 mg/kg/d
tolfenamic acid for 34 days. ANOVA revealed a signiﬁcant difference
in SP1 protein levels (F(2,11) ¼ 8.747, p ¼ 0.0053) (Fig. 6A). The
Tukey-Kramer HSD post hoc test indicated a signiﬁcant decrease of
SP1 after treatment with 5 mg/kg/d (HSD ¼ 4.145, p < 0.05, percent
change ¼ 43%) and 50 mg/kg/d (HSD ¼ 5.712, p < 0.01, percent
change ¼ 52%) tolfenamic acid (Fig. 6A).
Sp1 mRNA expression was evaluated for the different treatment
groups. Analysis of Sp1 mRNA levels showed that treatment with
tolfenamic acid did not alter the gene expression of Sp1 (F(2,16) ¼
0.082, p ¼ 0.922) (Fig. 6B).3.5. Reduction of APP protein and mRNA after treatment with
tolfenamic acid
Cortical APP normalized to b-actinwas analyzed byWestern blot
after treatmentwith 5 and 50mg/kg/d tolfenamic acid for 34 days or
with vehicle. ANOVA revealed that APP levels were lowered signif-
icantly (F(2,9) ¼ 8.377, p ¼ 0.009) (Fig. 7A). The Tukey-Kramer HSD
post hoc test indicated a signiﬁcant decrease in APP after treatment
with 5 mg/kg/d (HSD ¼ 4.877, p < 0.05, percent change ¼ 30.3%)
and 50 mg/kg/d (HSD ¼ 5.139, p < 0.05, percent change ¼ 32.5%)
tolfenamic acid (Fig. 7A).
In addition to analysis of APP protein levels, APP gene expression
was evaluated for the different treatment groups by real-time PCR.
ANOVA of APP mRNA levels revealed a signiﬁcant decrease in APP
gene expression (F(2,15) ¼ 5.238, p ¼ 0.019) (Fig. 7B). The Tukey-
Kramer HSD post hoc test indicated a signiﬁcant decrease of APP
mRNA after treatment with 5 mg/kg/d (HSD ¼ 3.885, p < 0.05,
percent change ¼ 50.3%) and 50 mg/kg/d (HSD ¼ 4.039, p < 0.05,
percent change¼52.3%) tolfenamic acid (Fig. 7B). The lowering of
APP was not associated with adverse effects (Adwan et al., 2011).Fig. 5. Working memory improvement in hemizygous APP yeast artiﬁcial chromo-
some transgenic mice, line R1.40, after administration of tolfenamic acid assessed by
spontaneous alternations in the Y-maze. Tolfenamic acid was administered by oral
gavage daily for 34 days. For details, see Section 2. Asterisk indicates that values are
signiﬁcantly different from vehicle control, as determined by 1-way analysis of vari-
ance with Tukey-Kramer post hoc test to compare all pairs of columns (p < 0.05),
obtained using GraphPad InStat 3 software. Vehicle n ¼ 6, 5 mg/kg/d n ¼ 6, and 50 mg/
kg/d n ¼ 7.
Fig. 6. Reduction of speciﬁcity protein (SP1) levels in the brain after treatment with
tolfenamic acid. Tolfenamic acid was administered by oral gavage daily for 34 days. For
details, see Section 2. (A) Western blot analysis of cortical SP1 levels as a ratio of the
housekeeping protein b-actin after treatment with 5 and 50 mg/kg/d of tolfenamic acid
for 34 days. (B) Cortical Sp1 messenger RNA (mRNA) levels determined by real-time
polymerase chain reaction. Asterisks indicate that values are signiﬁcantly different
from vehicle, as determined by 1-way analysis of variance with Tukey-Kramer post hoc
test to compare all pairs of columns (* p < 0.05, ** p < 0.01), obtained using GraphPad
InStat 3 software.
Fig. 7. Reduction of amyloid precursor protein (APP) levels in the brain after treatment
with tolfenamic acid. Tolfenamic acid was administered by oral gavage daily for
34 days. For details, see Section 2. (A) Western blot analysis of cortical APP levels as
a ratio of the housekeeping protein b-actin after treatment with 5 and 50 mg/kg/d of
tolfenamic acid for 34 days. (B) Cortical APP messenger RNA (mRNA) determined by
real-time polymerase chain reaction. Asterisk indicates that values are signiﬁcantly
different from vehicle, as determined by 1-way analysis of variance with Tukey-Kramer
post hoc test to compare all pairs of columns (p < 0.05), obtained using GraphPad
InStat 3 software.
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Ab1e42 levels
We measured the levels of cortical Ab1e40 and Ab1e42 in the
soluble and insoluble fractions of Tris-saline using IBL ELISA kits as
described in Section 2 (Morishima-Kawashima et al., 2000). ANOVA
showed that there was a signiﬁcant reduction in the soluble
(F(2,14) ¼ 3.89, p ¼ 0.04) (Fig. 8A) and the insoluble (F(2,14) ¼ 4.95,
p¼ 0.02) (Fig. 8B) Ab1e40 fractions. The Tukey-Kramer HSD post hoc
test indicated a signiﬁcant decrease in soluble Ab1e40 after treat-
ment with 50 mg/kg/d tolfenamic acid (HSD ¼ 3.91, p < 0.05,
percent change¼30.1%); however, the reduction in soluble Ab1e40
after treatment with 5 mg/kg/d did not reach signiﬁcance (HSD ¼
2.55, p > 0.05, percent change ¼ 21.3%) (Fig. 8A). Multiple-group
comparison showed a signiﬁcant decrease in the insoluble Ab1e40
fraction after treatment with both 5 mg/kg/d (HSD ¼ 3.73, p < 0.05,
percent change ¼ 35.2%) and 50 mg/kg/d (HSD ¼ 3.97, p < 0.05,
percent change ¼ 37.4%) tolfenamic acid (Fig. 8B).
Also, ANOVA showed a signiﬁcant decrease in the soluble
(F(2,14) ¼ 6.174, p ¼ 0.012) (Fig. 8C) and the insoluble (F(2,14) ¼
6.343, p ¼ 0.011) (Fig. 8D) Ab1e42 fractions. The Tukey-Kramer HSD
post hoc test indicated a signiﬁcant decrease in soluble Ab1e42 after
treatment with 5 mg/kg/d (HSD ¼ 4.18, p < 0.05, percent
change ¼ 22.3%) and 50 mg/kg/d (HSD ¼ 4.518, p < 0.05, percent
change ¼ 24.9%) tolfenamic acid (Fig. 8C). Similarly, multiple-
group comparison showed a signiﬁcant decrease in the insoluble
Ab1e42 fraction after treatmentwith5mg/kg/d (HSD¼4.72,p<0.05,
percent change ¼ 31.8%) and 50 mg/kg/d (HSD ¼ 4.79, p < 0.05,
percent change ¼ 37.7%) tolfenamic acid (Fig. 8D).We also observed that 5 and 50 mg/kg/d tolfenamic acid treat-
ment reduced total Ab1e42/Ab1e40 ratio to 16.3% and 19.9%,
respectively. However, this reduction in Ab1e42/Ab1e40 did not reach
statistical signiﬁcance (F(2,14) ¼ 1.788, p ¼ 0.203).
4. Discussion
Over the last 2 decades, more evidence has been garnered
regarding the association between chronic NSAIDs intake and up to
80% reduction in risk of AD incidence, slowing of disease progres-
sion, and reduction of microglial activation (Andersen et al., 1995;
Cote et al., 2012; Etminan et al., 2003; in t’ Veld et al., 2001; Lindsay
et al., 2002; McGeer et al., 1996; Stewart et al., 1997; Vlad et al.,
2008; Zandi et al., 2002). Several mechanisms have been pro-
posed to explain how NSAIDs could exert their effects on AD inde-
pendent of their cycolooxygenase (COX) inhibitory pathways.
Certain NSAIDs including indomethacin, ﬂufenamic acid, ibuprofen,
and fenoprofen are agonists for the nuclear transcriptional regulator
peroxisome proliferator-activated receptor g (PPARg) (Heneka et al.,
2011; Lehmann et al., 1997) that has been reported to be reduced in
AD brains (Sastre et al., 2006). PPARg activation results in a reduc-
tion in the levels of Ab-induced proinﬂammatory response of
microglia and monocytes and promotes Ab clearance by astrocytes
and microglia (Combs et al., 2000; Daynes and Jones, 2002;
Mandrekar-Colucci et al., 2012; Matsuo et al., 1996; Yue and
Mazzone, 2009). In addition, a PPARg responsive element has
been identiﬁed in the BACE1 gene promoter that is repressed by
PPARg binding resulting in a decrease in BACE1 expression (Sastre
Fig. 8. Reduction of soluble and insoluble amyloid beta (Ab)1e40 and Ab1e42 levels in the brain after treatment with tolfenamic acid. Tolfenamic acid was administered by oral gavage
daily for 34 days. For details, see Section 2. Enzyme-linked immunosorbent assay quantiﬁed Ab levels in the cortices of mice treated with 5 and 50 mg/kg/d of tolfenamic acid for 34
days. (A) Soluble Ab1e40, (B) insoluble Ab1e40, (C) soluble Ab1e42, and (D) insoluble Ab1e42 levels. Asterisk indicates that values are signiﬁcantly different from vehicle, as determined
1-way analysis of variance with Tukey-Kramer post hoc test to compare all pairs of columns (p < 0.05), obtained using GraphPad InStat 3 software.
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NSAIDs speciﬁcally lower Ab1e42 that was accompanied by a parallel
increase in Ab1e38 suggesting a minor g-secretase modulatory
effect without alteration of the Notch pathway. The speciﬁc Ab1e42
inhibition by that subset of NSAIDs was further studied by Zhou
et al. (2003), who concluded that the involvement of Rho-Rock
pathway in regulating APP processing and inhibition of Rho ac-
tivity by speciﬁc NSAIDs could preferentially reduce Ab1e42.
Tolfenamic acid, of all other NSAIDs, has the unique mechanism
of inducing the proteasome-dependent degradation of SP transcri-
ption factors including SP1, SP3, and SP4 and thereby decreasing the
expression of vascular endothelial growth factor (Abdelrahim et al.,
2006), which is involved in tumor progression and metastases.
Because of its SP degradation effects, tolfenamic acid has been
studied as a therapeutic agent for cancer and research has conﬁrmed
its antitumor effects (Abdelrahim et al., 2006; Basha et al., 2011;
Colon et al., 2011; Konduri et al., 2009).
Sp1 involvement in AD has been researched, and it was found
that its expression was elevated in the frontal cortex of AD brains
and in the brains of transgenic mouse models of AD (Citron et al.,
2008; Santpere et al., 2006). The elevation of Sp1 was accompa-
nied by an increase in COX-2, another Sp1 target gene, suggesting
interplay between inﬂammatory processes and Sp1edriven gene
expression (Citron et al., 2008). Sp1 binds to 50-GGGGCGGGGCerich
promoter genes such as APP and BACE1 genes, which are involved in
AD pathology, and Sp1 overexpression leads to induction of their
protein expression (Cai et al., 2001; Christensen et al., 2004; Citron
et al., 2008). We have reported that silencing of Sp1 gene by small
interfering RNA resulted in 70% decrease in the responsiveness of
the human APP promoter (Basha et al., 2005). Also, we have
demonstrated the colocalization of APP, Sp1, and Ab in various
regions of the brain (Brock et al., 2008). Thus, we proposed the
hypothesis that tolfenamic acid could interrupt the de novo
synthesis of APP and, consequently, alter the downstream levels of
Ab. This hypothesis was conﬁrmed when oral treatment withtolfenamic acid resulted in degradation of SP1 that was accompa-
nied by a reduction in cortical and hippocampal APP gene expres-
sion and protein and Ab peptide levels (Adwan et al., 2011). This was
further supported by measurements that demonstrated the pres-
ence of tolfenamic acid in the brain after intravenous administration
(Subaiea et al., 2011).
In the present study, we demonstrate that hemizygous, R1.40
transgenic mice exhibit cognitive deﬁcits on assessment of their
working memory and long-termmemory retention even before the
reported age of 24e26 months at which hemizygous R1.40 start to
suffer extensive Ab deposition (Lamb et al., 1999). Hemizygous
R1.40 mice start to exhibit 7e8 times more Ab1e42 levels compared
with wild types as early as 3e4 months of age (Lamb et al., 1999).
Thus, mice were studied at ages where there is a great increase in
Ab levels in the brain before plaque depositions. Spatial learning
was assessed in the hidden version of the MWM, and we found that
the transgenic mice were able to learn to escape to the hidden
platform in the daily training sessions (Fig. 2A). However, they
exhibitedmemory retention impairments in the probe trials as they
failed to retain the spatial location of the hidden platform with
increased delay (Fig. 2B, day 11). Working memory assessed in the
Y-maze was impaired in these mice as demonstrated by numerous
alternation errors and a lower alternation ratio compared with the
wild-type control group (Fig. 3). It has been proposed that recent
spatial memory is hippocampal dependent, whereas remote spatial
memory is dependent on the integrity of the medial prefrontal
cortex (Frankland and Bontempi, 2005; King et al., 1999; Teixeira
et al., 2006). In turn, working memory assessed in the Y-maze is
hippocampal and cortical dependent (Lalonde, 2002). This, together
with the ﬁndings that the R1.40 mouse model exhibits extensive
amyloid deposition in the cortical region compared with that
observed in the hippocampal formation (Hock et al., 2009), may
explain the observed results.
We report here that short-term tolfenamic acid administration
was able to improve themnemonic deﬁcits observed in hemizygous
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reverse the long-term memory retention deﬁcits seen in delayed
probe trials of the MWM experiment (Fig. 4B). In addition, the 50
mg/kg/d treatment group showed signiﬁcant improvement in the
Y-maze with less error in spontaneous alternations (Fig. 5).
However, the short-term treatment with 5 mg/kg/d group showed
only modest effects in reversing the memory deﬁcits in these mice.
Analysis of amyloid pathology markers indicated that both treat-
ment regimens, 5 and 50 mg/kg/d, were able to signiﬁcantly lower
the protein level of SP1 without altering its gene expression indi-
cating that the decrease in SP1 protein levels is not because of
a change in its de novo synthesis but is rather at the post-
translational level (Fig. 6A and B). Those results were similar to
our previous ﬁndings in C57BL/6 treated with tolfenamic acid
(Adwan et al., 2011). In addition, both tolfenamic acid doses
signiﬁcantly reduced the protein levels of APP and its gene
expression (Fig. 7A and B). Furthermore, levels of the soluble and
insoluble Ab1e40 and Ab1e42 were reduced by tolfenamic acid with
a trend toward lowering the insoluble fraction of Abmore than that
of the soluble fraction (Fig. 8). It is possible that tolfenamic acidmay
aid in clearance of insoluble Ab by a PPARg activation mechanism;
yet, it is not clear if tolfenamic acid activates PPARg as certain other
NSAIDs do.
Although tolfenamic acid was effective in lowering the amy-
loidogenic proteins with both doses, we observed dose-dependent
improvement in the cognitive deﬁcits. Whether longer period of
treatment with low-dose tolfenamic acid could result in signiﬁ-
cant improvements in cognitive function is yet to be studied.
However, it is essential to mention that tolfenamic acid produced
behavioral improvements after a rather short-term treatment
period compared with other FDA-approved AD drugs and NSAIDs.
For example, APP23 transgenic mice treated with 0.58 mg/kg/d
donepezil, an FDA-approved anticholinesterase drug for AD,
showed improved performance in MWM after 2 months of
treatment (Van Dam et al., 2008). In addition, memantine, another
FDA-approved drug for use in moderate to severe AD, has shown
to improve cognition in 3xTG-AD mice after 3 months of treat-
ment (Martinez-Coria et al., 2010). Also, triple transgenic mice
(APPswe, PS1M146V, and tauP301L) exhibited improved cognitive
functions after treatment with ibuprofen for 6 months (McKee
et al., 2008).
Many of the anti-amyloid drugs that failed in clinical trials
were anti-Ab monoclonal antibodies, g-secretase inhibitors,
BACE1 inhibitors, or certain NSAIDs that do not lower SP1
(Herrmann et al., 2011; Ozudogru and Lippa, 2012). This might be
because of either lack of efﬁcacy or ensuing adverse effects. The
main targets of these drugs were proteins involved at the end
stage of the amyloidogenic pathway. Tolfenamic acid interferes
with transcriptional pathways associated with AD-related genes;
thus, it acts at upstream pathways that can have impacts on
downstream events and is not dependent on protein events at the
end of the amyloidogenic pathways. Thus, it may hold better
promise for success.
In conclusion, tolfenamic acid is unique among other NSAIDs in
its ability to inhibit SP1 and thus interrupt APP de novo synthesis
and its Ab products. In this study, we demonstrated that adminis-
tration of 50 mg/kg/d tolfenamic acid for 34 days reversed the
cognitive deﬁcits in hemizygous, R1.40 transgenic mice. Consistent
with our previous published ﬁndings in C57BL/6 mice, SP1, the
amyloidogenic levels of APP and soluble and insoluble Ab1e40 and
Ab1e42 were markedly lowered by tolfenamic acid in AD transgenic
mice. These data provide further evidence that tolfenamic acid is
a promising therapeutic agent as a repurposed AD drug acting
through an alternative mechanism and should beneﬁt the sched-
uled clinical trials of this drug.Disclosure statement
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